BCR and B-cell non-Hodgkin lymphoma: The overall response rate (ORR) of evaluable patients was 60%, including a complete response (CR) rate of 16%, which indicates that pharmacological inhibition of BCR pathway holds promise in B-cell lymphoma treatment [8, 9].